Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 2 , Pages 80-87, June 2007

The history of PDT in Norway:

Part II. Recent advances in general PDT and ALA-PDT

  • Asta Juzeniene, PhD, MSc

      Affiliations

    • Department of Radiation Biology, The Norwegian Radium Hospital, Montebello N-0310, Oslo, Norway
    • Corresponding Author InformationCorresponding author. Tel.: +47 22935113; fax: +47 22934270.
    • ,
  • Johan Moan

      Affiliations

    • Department of Radiation Biology, The Norwegian Radium Hospital, Montebello N-0310, Oslo, Norway
    • Institute of Physics, Oslo University, Blindern 0316, Oslo, Norway

published online 28 December 2006.

Summary 

Generation of singlet oxygen and estimation of its lifetime, the oxygen effect, the subcellular localization of photosensitizers and their photodegradation during photodynamic therapy (PDT), the effects of PDT on DNA and chromosomes were described in the first part of our review.

In this review we discuss PDT in combination with other treatments (hyperthermia, ionizing radiation, electrotherapy, chemotherapeutic drugs) or with other agents; cell interactions and bystander effects in PDT; the influence of PDT on the cytoskeleton; a novel technology, named photochemical internalisation (PCI), for light-induced delivery of macromolecules and 5-aminolevulinic acid (ALA) PDT.

Lipophilic derivatives of ALA, instead of ALA itself, were proposed for induction of protoporphyrin IX (PpIX) in the treatment of superficial lesions. Based on this research a Norwegian company PhotoCure ASA was founded in 1993 with the aim to commercialise photodynamic technologies developed at the Norwegian Radium Hospital, the largest comprehensive cancer centre in Northern Europe. The company has two products on the market: Metvix® for treatment of basal cell carcinomas and actinic keratoses, and Hexvix® for fluorescence diagnosis of bladder cancer. New ALA derivatives for fluorescence diagnosis and treatment of early-stage cancers in internal organs, e.g. colon cancer, are currently being investigated.

Abbreviations: ALA, 5-aminolevulinic acid, AlPcSn, sulfonated aluminum phthalocyanines, BCCs, basal cell carcinomas, CP94, 2-diethyl-3-hydroxypyridin-4-one, DFO, desferrioxamine, DMSO, dimethylsulphoxide, EDTA, ethylenediaminetetraacetic acid, HAL, hexyl 5-aminolevulinate, HpD, hematoporphyrin derivative, FD, fluorescence diagnosis, MAL, methyl 5-aminolevulinate, m-THPC, meso-tetra(hydroxyphenyl)chlorin, PDT, photodynamic therapy, PCI, photochemical internalisation, PpIX, protoporphyrin IX, 1O2, singlet oxygen, TPPSn, sulfonated tetraphenylporphines

Keywords: Photodynamic therapy, Fluorescence diagnosis, Photosensitizers, Singlet oxygen, 5-Aminolevulinic acid, Protoporphyrin IX

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1572-1000(06)00149-9

doi:10.1016/j.pdpdt.2006.11.001

Photodiagnosis and Photodynamic Therapy
Volume 4, Issue 2 , Pages 80-87, June 2007

Article Tools